# Commission Implementing Decision (EU) 2018/945 of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions (Text with EEA relevance), Division: Laboratory Criteria

Extent: E+W+S+N.I.

At least one of the following three:
(i) Isolation of Bordetella pertussis from a clinical specimen
(ii) Detection of Bordetella pertussis nucleic acid in a clinical specimen
(iii) Bordetella pertussis specific antibody response
Direct diagnosis (i)-(ii): Bordetella pertussis and its nucleic acid are best isolated/detected from nasopharyngeal samples.
Indirect diagnosis (iii): if possible ELISA should be performed using highly purified Pertussis Toxin and WHO reference sera as a standard. Results need to interpreted according to pertussis vaccination status. If vaccinated within the last few years before specimen collection, the titre of specific antibodies against Bordetella pertussis toxin may be a consequence of, or modified by, previous vaccination.

---
Source: https://www.legislation.gov.uk/eudn/2018/945/annex/II/division/3/division/3.30/division/2 (the official version)
Page: https://openlegislation.uk/eu-decision-2018-945/annex-II/division-3/division-3.30/division-2
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.